Evidence map›Paper›PMID 42004054›Full record

ArticleAmerican journal of cancer research2026

CBX3 promotes epithelial-mesenchymal transition in synovial sarcoma via the SHH signaling pathway.

Yachao Sun, Zhibing Dai, Junwei Du, Maierdanjian Maihemuti, Suzhi Ji, Renbing Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yachao SunDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.
Zhibing DaiDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.
Junwei DuDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.
Maierdanjian MaihemutiDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.
Suzhi JiDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.
Renbing JiangDepartment of Bone and Soft Tissue Neoplasms and Melanoma, The Affiliated Cancer Hospital of Xinjiang Medical University Urumqi 830011, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synovial sarcoma (SS) is a malignant mesenchymal tumor of uncertain histogenesis, representing approximately 5% to 10% of all soft tissue sarcomas. It predominantly affects adolescents and young adults. The role of CBX3 (Chromobox homolog 3) in Synovial sarcoma progression, particularly in relation to epithelial mesenchymal transition (EMT), remains unclear. This study aimed to investigate the functional role of CBX3 in synovial sarcoma and to elucidate the underlying molecular mechanisms by which it regulates EMT. Human synovial sarcoma cell lines (SYO-1, HS-SY-II, YaFuSS, and Fuji) and the immortalized human keratinocyte line (HaCaT) were used for

Indexed as

CBX3epithelial mesenchymal transitionferroptosismitochondrial oxidationSynovial sarcoma

Identifiers

PMID42004054
PMCPMC13090498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.